

SynBuild




Synbuild, LLC

**A gene building company of
a new generation**


Synthetic Genes

Who needs them and why?

- New drugs and diagnostics
- New vaccines and therapeutics
- Green energy and biofuels
- New materials and polymers
- Eco-friendly technologies




Fast Growing Market




The Problem

Long and complex genes cannot be built quickly and cost efficiently




Short and simple genes
2 weeks



Long and complex genes
2+ months

The Solution


Eliminate the Repair



Competitors

Need to Repair

Months



Synbuild

Perfect w/out Repair

Days

The Technology

Block-based gene assembly

Converts raw material into blocks

Selects blocks for perfection

Combines perfect blocks into flawless genes

Validated

Patent Pending

Exclusively Licensed

The Benefits

- **Faster**
 - days vs. weeks
- **Cheaper**
 - 0.1c per base vs. 10c per base
- **Better**
 - perfect vs. ~10 errors per av. gene
- **Universal**
 - equally efficient for genes of any size and complexity

New Market Segment Long & Complex Genes

- Low competition
 - We can, others cannot
- Fast growing demand
 - Every third gene in genome
- High market price
 - \$1.5 per base and up

Customer Base

Industry	Application	Gene Cat Source	Delivered to date	Orders under negotiations
Academia	Vaccine discovery	Small Bacterial	>1,000	
Academia	Vaccine discovery	Various Bacterial	100	~100 L&C genes in 2010
Biotechnology	Protein production	Mostly L&C Various	50	~100 genes per year
Pharmaceuticals	Drug discovery	L&C Human	10	~10,000 genes in 2-3 years
Immunology	Diagnostics	Various Human		~25,000 genes in 5 years

Business Plan

- 2009** – Raise at least \$600,000
- 2010** – Hire & train staff, start commercial operations
- 2011** – Scale up production
- 2012 – 2014** – Further growth and technology development
- 2014** – Sale of business/technology

The Team


CEO/CSO – Dr. Alex Borovkov

- Founder, inventor of the technology
- Outstanding record of innovative research
- Experienced program manager and coordinator
- Expert in HTP gene assembling, cloning, and expression

Business Advisory Board

- Jon McGarity, President & CEO, EthiX Associates
- Ken Noonan, Partner, Advanced Technology Ventures
- Kevin Weber, Founder & President, BioMark Partners

Financial Outlook



Revenue	\$1,087,500	\$3,443,750	\$6,543,125	\$12,431,938	\$23,620,681
Gross Profit	\$727,500	\$2,503,200	\$4,777,900	\$9,082,265	\$17,012,906
Net income	(\$67,676)	\$1,250,026	\$2,725,160	\$5,694,449	\$11,090,948
Cash from Operations	(\$502,502)	\$186,427	\$1,175,334	\$3,024,815	\$6,251,474